Agoura Hills, CA – According to filings with the U.S. Securities and Exchange Commission, A2 Biotherapeutics is raising $58,027,099.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Scott Foraker played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About A2 Biotherapeutics

A2 is a biotechnology company, focused on cell therapy, that aspires to beat cancer via tumor-specific targeting. The company was founded in 2018 by Alexander Kamb, Michael Gallo and Paul Kang and has raised financing of $136 million (The Column Group, Vida Ventures, Samsara BioCapital, Nextech Invest, Casdin Capital, Euclidean Capital, UC Investments (Office of the Chief Investment Officer of the Regents) and Hartford HealthCare Endowment. We are currently advancing a pipeline of programs towards the clinic.

To learn more about A2 Biotherapeutics, visit http://www.a2bio.com/

Contact:
Scott Foraker, President and Chief Executive Officer
805-491-1988
https://www.linkedin.com/in/scott-foraker-76765a5/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved